Big Pharma firms touted growth in China; Genentech sues ex-staffers and biosim company; Janssen licenses Yuhan's potential Tagrisso rival.
Hikma, which has established itself as a top sterile injectables manufacturer in the U.S., is now picking up a production plant in Vietnam.
Ex-Roche scientists were charged with stealing trade secrets; Astellas invested in gene and cell therapy; Takeda touted growth in key focus areas.
Merck's RotaTeq won China approval in April and a launch is underway, but meanwhile, the company is reducing its shipments to low-income countries.
The FDA says a probable cancer-causing ingredient has been found in yet another blood pressure treatment in the U.S.
The FDA continues to find issues with Dr. Reddy’s oncology formulation facility at Duvvada, one of three cited in a warning letter.
Takeda is eager to close its Shire deal and take the specialty pharma under its wing, but for now it's highlighting a few strengths in its own business.
India's Glenmark is opening a $100 million plant in North Carolina to make generic drugs.
Amid reports that it will sell Shire's Xiidra and Natpara, Takeda said it may sell SHP647, a phase 3 bowel drug that would overlap its own Entyvio.
Biogen and Eisai defend Alzheimer's drug; Taiho and Servier's Lonsurf shows positive gastric cancer data; J&J pays $2.1 billion for Japan's…